Brin M, Droz J P, Caillaud J M, Bellet D, Amiel J L, Brulé G
J Urol (Paris). 1982;88(6):345-7.
Cerebral metastases occur in 6% of cases of testicular cancer. In our study of 5 cases they occurred during the course of the disease (with a delay of 4-18 months, at the same time as pulmonary and abdominal metastases). The prognosis in these cases is poor (presence of choriocarcinomatous or vitelline elements, advanced stages). The diagnosis is easily established (clinical, encephalogram, scanner); the prognosis is hopeless (5 deaths in 3-90 days). When a metastasis is the first diagnostic clue (one case), the prognosis is slightly better (9 month survival). The incidence of cerebral metastasis is the same now as it was before the introduction of effective chemotherapy in patients who die from testicular cancer, but the death rate from this malignancy has decreased since the introduction of active chemotherapy with cisplatin. Hence, there is no indication for prophylactic treatment for cerebral metastases in patients in remission since metastases only appear in cases which are resistant to treatment.
脑转移发生在6%的睾丸癌病例中。在我们对5例患者的研究中,脑转移发生在疾病过程中(延迟4 - 18个月,与肺和腹部转移同时出现)。这些病例的预后很差(存在绒毛膜癌或卵黄囊成分,处于晚期)。诊断很容易确立(临床症状、脑电图、扫描仪检查);预后无望(3 - 90天内5例死亡)。当转移是首个诊断线索时(1例),预后稍好(存活9个月)。脑转移的发生率在死于睾丸癌的患者中,现在与有效化疗引入之前相同,但自从引入顺铂积极化疗后,这种恶性肿瘤的死亡率有所下降。因此,对于处于缓解期的患者,没有预防性治疗脑转移的指征,因为转移仅出现在对治疗耐药的病例中。